These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26811013)

  • 61. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.
    Wilhelm M; Smetak M; Reimer P; Geissinger E; Ruediger T; Metzner B; Schmitz N; Engert A; Schaefer-Eckart K; Birkmann J
    Blood Cancer J; 2016 Jul; 6(7):e452. PubMed ID: 27471868
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma.
    Irlé C; Weintraub J
    Case Rep Hematol; 2016; 2016():8175957. PubMed ID: 27648317
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States.
    Adams SV; Newcomb PA; Shustov AR
    J Clin Oncol; 2016 Mar; 34(9):963-71. PubMed ID: 26962200
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
    Marchi E; Raufi AG; O'Connor OA
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Genetic Landscape and Classification of Peripheral T Cell Lymphomas.
    Sandell RF; Boddicker RL; Feldman AL
    Curr Oncol Rep; 2017 Apr; 19(4):28. PubMed ID: 28303495
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
    Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Hosing C; Nieto YL; Oki Y
    Br J Haematol; 2017 Mar; 176(5):750-758. PubMed ID: 27983760
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?
    Phillips EH; Hodson A; Hermine O; Bazarbachi A; Cwynarski K
    Bone Marrow Transplant; 2016 Dec; 51(12):1549-1555. PubMed ID: 27618683
    [TBL] [Abstract][Full Text] [Related]  

  • 68. First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator’s Choice (LUMIERE trial; NCT01482962).
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):12-3. PubMed ID: 27466629
    [No Abstract]   [Full Text] [Related]  

  • 69. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.
    Schmitz N; de Leval L
    Br J Haematol; 2017 Mar; 176(6):851-866. PubMed ID: 27982416
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
    Alperovich A; Younes A
    Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mogamulizumab for the treatment of T-cell lymphoma.
    Makita S; Tobinai K
    Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The diagnosis and management of NK/T-cell lymphomas.
    Tse E; Kwong YL
    J Hematol Oncol; 2017 Apr; 10(1):85. PubMed ID: 28410601
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Peripheral T-cell lymphoma, not otherwise specified.
    Broccoli A; Zinzani PL
    Blood; 2017 Mar; 129(9):1103-1112. PubMed ID: 28115372
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Experimental treatment strategies in primary cutaneous T-cell lymphomas.
    Rozati S; Kim YH
    Curr Opin Oncol; 2016 Mar; 28(2):166-71. PubMed ID: 26844985
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The aggressive peripheral T-cell lymphomas: 2017.
    Armitage JO
    Am J Hematol; 2017 Jul; 92(7):706-715. PubMed ID: 28516671
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Review of Current Disease Understanding and Therapeutic Approaches.
    Al-Zahrani M; Savage KJ
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):189-207. PubMed ID: 28340873
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review.
    Yang YT; Tai CJ; Chen C; Wu HC; Mikhaylichenko N; Chiu HT; Chen YY; Hsu YE
    PLoS One; 2016; 11(10):e0161811. PubMed ID: 27711130
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The curious origins of angioimmunoblastic T-cell lymphoma.
    Cortés JR; Palomero T
    Curr Opin Hematol; 2016 Jul; 23(4):434-43. PubMed ID: 27177312
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
    Martinez-Escala ME; Kuzel TM; Kaplan JB; Petrich A; Nardone B; Rosen ST; Guitart J
    JAMA Oncol; 2016 Jun; 2(6):790-3. PubMed ID: 27054291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.